Novartis may sell assets from its diagnostic imaging unit: Report

Drugmaker Novartis is weighing whether to sell assets from its radiopharmaceuticals unit, Advanced Accelerator Applications, Bloomberg reported Tuesday citing unnamed sources with knowledge of the matter.

The Swiss company is already is in the initial stages of seeking buyers for some of its imaging products, used for diagnosing certain cancers, cardiovascular and neurological disorders.

“Deliberations are ongoing and there’s no certainty they’ll result in any transaction,” Bloomberg wrote Oct. 3, while noting that Novartis declined to comment on the report.

Read more from the news outlet at the link below (subscription required).

Marty Stempniak

Marty Stempniak has covered healthcare since 2012, with his byline appearing in the American Hospital Association's member magazine, Modern Healthcare and McKnight's. Prior to that, he wrote about village government and local business for his hometown newspaper in Oak Park, Illinois. He won a Peter Lisagor and Gold EXCEL awards in 2017 for his coverage of the opioid epidemic. 

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.

Trimed Popup
Trimed Popup